Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140939 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
A Phase 3 study, sponsored by Caliway Biopharmaceuticals Co..
- Not yet
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT07140939: Clinical Trial Phase 3 study, sponsored by Caliway Biopharmaceuticals Co..
NCT07140939 is a Phase 3 study that has not yet begun recruiting, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07140939, a Phase 3 study, has not yet begun recruiting, sponsored by Caliway Biopharmaceuticals Co..
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Primary Outcome
Measured by MRI and a 5-point ordinal scale
Interventions
- DRUG CBL-514 Injection
- OTHER 0.9% Sodium Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
What is known before NCT07140939 opens enrollment
NCT07140939 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which CBL-514 Injection is the first listed.
NCT07140939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07140939 about?
NCT07140939 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat". A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
What is the current status of trial NCT07140939?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-07. Estimated completion is 2027-07.
What interventions are being tested in trial NCT07140939?
The interventions under investigation include: CBL-514 Injection (DRUG), 0.9% Sodium Chloride (OTHER).
Who is sponsoring clinical trial NCT07140939?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07140939's enrollment target sits among peer trials
300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia